Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Shore Unpacks Treatment Advances for Patients With Urologic Cancers

November 11th 2022, 2:00pm

LUGPA Annual Meeting

Neal Shore, MD, FACS, highlights the effect of genetic testing on the treatment paradigm of prostate cancer and the evolving treatment landscape for metastatic castration resistant prostate cancer.

Dr. Perl on Genetic Testing and Targeted Therapies in AML

November 10th 2022, 10:30pm

PER® Chemotherapy Foundation Symposium (CFS)

Alexander E. Perl, MD, MS, associate professor, medicine, the Hospital of the University of Pennsylvania, discusses why genetic testing is important for determining targeted therapies for patients with acute myeloid leukemia.

Dr. Kris on Atezolizumab in NSCLC

November 10th 2022, 10:25pm

PER® Chemotherapy Foundation Symposium (CFS)

Mark G. Kris, MD, discusses the role of atezolizumab in patients with non–small cell lung cancer.

Every Patient With Metastatic Melanoma “Deserves a Shot at Nivolumab/Ipilimumab,” Weber Says

November 10th 2022, 9:00pm

PER® Chemotherapy Foundation Symposium (CFS)

The combination of nivolumab and ipilimumab have shown overall survival benefit in patients with metastatic melanoma, according to long-term follow-up data, and other studies’ results highlight the efficacy and toxicity benefits of different sequences of the combination.

Rugo Highlights Key Priorities for the Future of Breast Cancer Research

November 10th 2022, 8:50pm

PER® Chemotherapy Foundation Symposium (CFS)

Research in breast cancer has led to remarkable progress in the understanding and management of the disease, but the oncology community can always do more to optimize treatment outcomes for patients.

PARP Maintenance Therapy Provides Varying Benefit in Advanced Ovarian Cancer

November 10th 2022, 8:49pm

PER® Chemotherapy Foundation Symposium (CFS)

The benefit of PARP maintenance therapy for patients with advanced ovarian cancer differs depending on a number of factors, including the homologous recombination and BRCA mutation status of the tumor.

Neoantigen TCR T-cell Therapy Shows Early Proof-of-Concept in Solid Tumors

November 10th 2022, 8:30pm

SITC Meeting

A personalized neoantigen-specific and off-the-shelf T cell receptor T-cell therapy utilized through CRISPR gene editing technology demonstrated feasibility and tolerability in 16 patients across multiple tumor types, according to first-in-human phase 1a findings.

Sequencing Strategies, Improving QOL Are Top Priorities in Neuroendocrine Neoplasm Treatment

November 10th 2022, 3:30pm

PER® Chemotherapy Foundation Symposium (CFS)

Diane Reidy-Lagunes, MD, discussed the role of next-generation sequencing paired with systemic therapies and the option of peptide receptor radionuclide therapy in neuroendocrine malignancies.

Breast Cancer Advances in 2022 Shape CFS Agenda

November 10th 2022, 3:20pm

PER® Chemotherapy Foundation Symposium (CFS)

Emerging novel therapies, new stratification factors, and sequencing challenges because of the new classifications for patients with breast cancer will be topics of discussion at the 40th Annual Chemotherapy Foundation Symposium® during the breast cancer sessions.

Novel Agents Replace CAR T-Cell Therapy in Later-Line, Relapsed/Refractory DLBCL

November 9th 2022, 8:30pm

PER® Chemotherapy Foundation Symposium (CFS)

New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma in addition to chimeric antigen receptor T-cell therapy, which has moved up into the second line.

Addressing Intolerance and Resistance to BTK Inhibition Is Next Frontier in CLL Drug Development

November 9th 2022, 8:20pm

PER® Chemotherapy Foundation Symposium (CFS)

The development of agents to address intolerance and acquired resistance to BTK inhibitors addresses 2 of the major unmet needs for patients with chronic lymphocytic leukemia.

Frontline Setting Boasts Multiple Treatment Options for Patients With ALL

November 9th 2022, 8:00pm

PER® Chemotherapy Foundation Symposium (CFS)

Clinicians treating patients with newly diagnosed acute lymphocytic leukemia now have multiple options at their disposal, including tyrosine kinase inhibitors, blinatumomab, and multiagent chemotherapy-based regimens, with more options aiming to enter the treatment paradigm.

Petrylak Previews Shift in Sequencing Paradigm in Urothelial Cancer

November 9th 2022, 6:00pm

PER® Chemotherapy Foundation Symposium (CFS)

Daniel P. Petrylak, MD, highlights the use of checkpoint inhibitors, antibody-drug conjugates, and FGFR inhibitors in urothelial cancer and the current sequencing hurdles in the paradigm.

Innovations Are Poised to Lead MPN/MDS Treatment Landscape in a Positive Direction

November 9th 2022, 4:00pm

PER® Chemotherapy Foundation Symposium (CFS)

Ahead of the 40th Annual Chemotherapy Foundation Symposium, Pinkal Desai, MD, addresses the evolving role of targeted therapies in MDS and how clinicians can characterize MDS risk.

40th Annual CFS® Highlights New Frontiers in Cancer Care

November 9th 2022, 3:04pm

PER® Chemotherapy Foundation Symposium (CFS)

The Chemotherapy Foundation Symposium® returns to New York City for its 40th annual meeting with a 3-day program that will deliver the latest updates across the gamut of oncology care.

Emerging Therapies Prompt Nuanced AE Management in Kidney Cancer

November 6th 2022, 11:00am

International Kidney Cancer Symposium

Kiran Virdee, RN, BSN, CCRN-K, outlines the best practices for the management of adverse effects during the treatment of kidney cancer.

Investigators Debate Frontline Doublet Vs Triplet Therapy in RCC

November 5th 2022, 12:30pm

International Kidney Cancer Symposium

Rana M. McKay, MD, and Yousef Zakharia, MD, debate the pros and cons of doublet vs triplet combination therapies in the frontline setting for patients with renal cell carcinoma.

Tivozanib Maintains Long-Term PFS Benefit Over Sorafenib in Relapsed/Refractory RCC

November 5th 2022, 12:00pm

International Kidney Cancer Symposium

Tivozanib continued to display a progression­-free survival benefit and rates vs sorafenib in patients with relapsed/refractory renal cell carcinoma who received 2 or 3 prior systemic regimens.

Dr. McKay on Tivozanib Plus Nivolumab in Advanced RCC

November 4th 2022, 8:45pm

International Kidney Cancer Symposium

Rana R. McKay, MD, discusses the rationale for combining tivozanib with nivolumab in heavily pretreated patients with renal cell carcinoma.

Nivolumab/Ipilimumab Improves Survival in Untreated, Advanced Sarcomatoid RCC

November 4th 2022, 8:30pm

International Kidney Cancer Symposium

The combination of nivolumab and ipilimumab led to significant improvements in survival vs sunitinib in patients with intermediate- and poor-risk renal cell carcinoma with sarcomatoid features.